New York: Health regulators issued recommendations to ensure the safe production of the blood-clot prevention drug heparin, four years after a contamination involving the widely used product set off concerns about the global pharmaceutical supply chain.The draft guidance, posted on the website of the Food and Drug Administration on Friday, is designed to help manufacturers of active ingredients, finished products and others better control heparin to avoid contamination.
Pakistan violates ceasefire again, opens fire at RS Pura sector in J&K
PM Modi to lead BJP Parliamentary Party in both houses of Parliament
BJP will continue animosity with Moradabad SSP for years: Laxmikant Bajpai
UPSC aspirants protest outside Rajnath Singh`s residence